CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting

Professor Nikhil Vasdev to Present Results of a Recently Published Clinical Trial Featuring AirSeal^® technology

CONMED Corporation (NYSE:CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.

During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdominal insufflators, CONMED’s AirSeal^® Insufflation System and Stryker’s PneumoClear Insufflator.

TITLE: Utilising intra-operative artificial intelligence to investigate the difference in nociceptive stimulus between 2 different abdominal insufflators during a Robotic Prostatectomy (RALP Clinical Trial)

DATE: Friday, July 24

TIME: 8:02 AM ET

LOCATION: 314

The trial included 40 patients with localized prostate cancer who underwent a robotic prostatectomy, with either AirSeal or PneumoClear used for the management of low-pressure pneumoperitoneum (8 mmHg). Differences in the levels of significant intra-operative nociception between the two insufflators were recorded using an artificial intelligence device. The AirSeal arm of the trial had fewer significant nociceptive events per recorded hour than the PneumoClear arm (20.7 vs. 33.5, p = 0.041). Additionally, shorter procedure times (p = 0.045), console times (p = 0.045), and blood loss (p < 0.001) were seen in the AirSeal arm. The results of the trial were published in the open access journal, JUI Compass, in May, 2026 and are available via the following link: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.70226

In connection with its participation, CONMED will host a session that explores how low-pressure insufflation is redefining intraoperative performance to support surgical efficiency and enable enhanced patient recovery. The session will feature Amit Taggar, MD, FACS, FAMBS, FICS, Gabe Mena, MD FASA, Philip Woodworth, MD, FACS, and Rahila Essani, MD, FACS, FACRS.

TITLE: Why Stability at Low Pressure in Robotic Surgery Matters Intraoperatively and for Patients

DATE: Friday, July 24

TIME: 12:30 PM ET

LOCATION: Diplomat Room 4

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260720880337/en/

CONMED Corporation

Dalton Henry

Investor Relations Analyst

IR@conmed.com